成人晚期急性B淋巴细胞白血病的免疫治疗

RobertPeter Gale; DavidKegyes; CiprianJitaru; CiprianTomuleasa

doi:10.13201/j.issn.1004-2806.2025.03.001

(编者按

Ethics Not applicable.

Data Availability Not applicable.

)

成人晚期急性B淋巴细胞白血病的免疫治疗

- 1.
  英国伦敦帝国理工学院血液学中心
- 2.
  罗马尼亚鲁里欧·哈提甘努医药大学血液学-医学未来高级医学研究中心
- 3.
  罗马尼亚克卢日纳波卡Ion Chiricuta肿瘤研究所血液学系

详细信息

作者简介:
Robert Peter Gale，Leukemia杂志主编，加州大学洛杉矶分校医学中心医学教授，伦敦帝国理工学院血液学专业客座教授，洛杉矶Salick Health Care (SHc) Inc.(现为Aptium Oncology)高级医师，负责骨髓和血细胞移植，许多血液学、肿瘤学、免疫学、移植和内科医学科学期刊的编辑、联合编辑和/或审稿人

通讯作者: Robert Peter Gale, E-mail: robertpetergale@alumni.ucla.edu

中图分类号: R733.71

收稿日期: 2024-12-31

刊出日期: 2025-03-01

Immune therapy of advanced B-cell acute lymphoblastic leukaemia in adults

- 1.
  Centre for Haematology, Imperial College of Science, Technology and Medicine, London, UK
- 2.
  Department of Hematology-Medfuture Research Center for Advanced Medicine, Iuliu Haţieganu University of Medicine and Pharmacy Cluj Napoca, Romania
- 3.
  Department of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania

More Information

Corresponding author: Robert Peter Gale, E-mail: robertpetergale@alumni.ucla.edu

Received Date: 31 December 2024

Publish Date: 01 March 2025

摘要

摘要: 成人急性B淋巴细胞白血病(acute B-cell lymphoblastic leukaemia，B-ALL)患者中部分人群尚无法通过现有疗法获得治愈，新近批准的数款免疫疗法在该群体中显示安全有效。本述评旨在对晚期成人B-ALL免疫疗法的临床研究数据进行概要总结，包括利妥昔单抗、贝林妥欧单抗、奥加伊妥珠单抗、替沙仑赛、brexucabtagene autoleucel和obecabtagene autoleucel。
- 急性B淋巴细胞白血病 /
- 急性淋巴细胞白血病 /
- 免疫疗法 /
- 贝林妥欧单抗 /
- 奥加伊妥珠单抗 /
- 替沙仑赛 /
- brexucabtagene autoleucel
Abstract: Many adults with acute B-cell lymphoblastic leukaemia(B-ALL) are not cured by current therapies. However, several newly-approved immune therapies are safe and effective in this setting. We summarize data on immune therapies of advanced adult B-cell ALL including rituximab, blinatumomab, inotuzumab ozogamicin, tisagenlecleucel, brexucabtagene autoleucel and obecabtagene autoleucel.
- B-cell acute lymphoblastic leukaemia /
- ALL /
- immune therapy /
- blinatumomab /
- inotuzumab ozogamicin /
- tisagenlecleucel /
- brexucabtagene autoleucel

HTML全文

图 1 4款美国FDA批准的免疫治疗药物结构

下载: 全尺寸图片幻灯片

图 2 CAR-T细胞制备和治疗流程

下载: 全尺寸图片幻灯片

图 3 国际CIBMTR关于18岁以上患者接受HLA相合亲属的异基因造血干细胞移植的研究结果

下载: 全尺寸图片幻灯片

Figure 1. Structures of 4 USFDA-approved immune therapies

下载: 全尺寸图片幻灯片

Figure 2. Steps in CAR-T-cell manufacturing and therapy

下载: 全尺寸图片幻灯片

Figure 3. Results of allotransplants in people >18 years from HLA-matched relatives analyzed by the Center for Blood and Marrow Transplant Research (CIBMTR)

下载: 全尺寸图片幻灯片

参考文献(8)

[1]	Kegyes D, Jitaru C, Ghiaur G, et al. Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia[J]. Blood Rev, 2023, 59: 101042. doi: 10.1016/j.blre.2023.101042
[2]	Kegyes D, Ghiaur G, Bancos A, et al. Immune therapies of B-cell acute lymphoblastic leukaemia in children and adults[J]. Crit Rev Oncol Hematol, 2024, 196: 104317. doi: 10.1016/j.critrevonc.2024.104317
[3]	Maury S, Chevret S, Thomas X, et al. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia[J]. N Engl J Med, 2016, 375(11): 1044-1053. doi: 10.1056/NEJMoa1605085
[4]	Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia[J]. N Engl J Med, 2017, 376(9): 836-847. doi: 10.1056/NEJMoa1609783
[5]	Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia[J]. N Engl J Med, 2016, 375(8): 740-753. doi: 10.1056/NEJMoa1509277
[6]	Laetsch TW, Maude SL, Rives S, et al. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA trial[J]. J Clin Oncol, 2023, 41(9): 1664-1669. doi: 10.1200/JCO.22.00642
[7]	Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study[J]. Lancet, 2021, 398(10299): 491-502. doi: 10.1016/S0140-6736(21)01222-8
[8]	Roddie C, Sandhu KS, Tholouli E, et al. Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia[J]. N Engl J Med, 2024, 391(23): 2219-2230. doi: 10.1056/NEJMoa2406526